<DOC>
	<DOCNO>NCT01341457</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability LY2603618 combination standard dose gemcitabine global recommend dose LY2603618 Japanese patient solid advanced metastatic tumor .</brief_summary>
	<brief_title>A Study LY2603618 Combination With Gemcitabine Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Have histological cytological image evidence diagnosis cancer advance and/or metastatic disease Patient plan gemcitabine therapy propose dos he/she able benefit standard therapy and/or therapy know provide clinical benefit standard therapy advance and/or metastatic disease globally Have give write informed consent prior studyspecific procedure Have adequate hematologic , hepatic renal function Have performance status 02 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous therapy cancer , include chemotherapy , cancerrelated hormonal therapy , investigational therapy least 30 day ( 42 day mitomycin C nitrosoureas ) prior study enrollment recover acute effect therapy Prior radiation therapy treatment cancer allow less 25 % bone marrow , patient must recover acute toxic effect treatment prior study enrollment . Prior radiation whole pelvis allow . Prior radiotherapy must complete least 30 day prior study enrollment Males female reproductive potential must agree use medically approve contraceptive precaution study 3 month last infusion study drug Females child bear potential ( surgically sterilize menarche 1 year post menopause ) must negative urine pregnancy test le 7 day prior enrollment Are reliable willing make available duration study willing follow study procedure Have estimate life expectancy least 12 week Are currently enrol , discontinue within last 30 day , clinical study involve offlabel use investigational drug device ( study drug use study ) , concurrently enrol type medical research judge scientifically medically compatible study Have serious preexist medical condition serious concomitant systemic disorder would compromise safety patient his/her ability complete study Have interstitial pneumonitis pulmonary fibrosis , previous history Have symptomatic central nervous system malignancy metastasis Have current active infection Females pregnant lactate Have know positive test result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBSAg ) , hepatitis C antibody ( HCAb ) Patients acute chronic leukemia disease likely significant bone marrow infiltration Have previously complete withdrawn study study investigate LY2603618 Chk1 inhibitor Have know allergy gemcitabine LY2603618 ingredient gemcitabine LY2603618 ( like CaptisolÂ® ) Have abnormal ECG result would put patient unnecessary risk opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>